Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. 1997

D I Marks, and B W Kurz, and M P Link, and E Ng, and J J Shuster, and S J Lauer, and D Carroll, and I Brodsky, and D S Haines
Department of Medicine, Allegheny University of the Health Sciences, Philadelphia, PA 19102, USA.

OBJECTIVE To determine whether potential alteration in p53 function through p53 gene mutation or mdm-2 overexpression correlates with early treatment failure in childhood acute lymphoblastic leukemia (ALL). METHODS Diagnostic marrow samples from 34 children were analyzed for p53 gene alterations by western blot and SSCP/DNA sequence analysis and for mdm-2 overexpression by western blot analysis. These samples were derived from two groups of children with ALL: 17 good outcome patients who are in long-term continuous complete remission and 17 poor outcome patients who did not achieve a complete remission or relapsed within 6 months of achieving remission. RESULTS Two children within the poor outcome group were found to have p53 gene mutations. Furthermore, five poor outcome patients were shown to have greater than 10-fold overexpression of mdm-2 protein compared with the mean level of mdm-2 protein measured in the good outcome group. Aberrant p53 protein expression was found in only one good outcome patient, whereas no good outcome children were found to have elevated levels (> 10-fold) of mdm-2 protein. CONCLUSIONS We show for the first time that potential alteration in p53 function in childhood ALL is more common (P = .036) in cases of early treatment failure than in children who remain in long-term continuous remission.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009687 Nuclear Proteins Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus. Nucleolar Protein,Nucleolar Proteins,Nuclear Protein,Protein, Nuclear,Protein, Nucleolar,Proteins, Nuclear,Proteins, Nucleolar
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016158 Genes, p53 Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53. Genes, TP53,TP53 Genes,p53 Genes,Gene, TP53,Gene, p53,TP53 Gene,p53 Gene
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53

Related Publications

D I Marks, and B W Kurz, and M P Link, and E Ng, and J J Shuster, and S J Lauer, and D Carroll, and I Brodsky, and D S Haines
January 1994, Anticancer research,
D I Marks, and B W Kurz, and M P Link, and E Ng, and J J Shuster, and S J Lauer, and D Carroll, and I Brodsky, and D S Haines
November 1994, Molecular and cellular biology,
D I Marks, and B W Kurz, and M P Link, and E Ng, and J J Shuster, and S J Lauer, and D Carroll, and I Brodsky, and D S Haines
January 1986, Medical and pediatric oncology,
D I Marks, and B W Kurz, and M P Link, and E Ng, and J J Shuster, and S J Lauer, and D Carroll, and I Brodsky, and D S Haines
January 2020, PloS one,
D I Marks, and B W Kurz, and M P Link, and E Ng, and J J Shuster, and S J Lauer, and D Carroll, and I Brodsky, and D S Haines
August 1991, Cancer,
D I Marks, and B W Kurz, and M P Link, and E Ng, and J J Shuster, and S J Lauer, and D Carroll, and I Brodsky, and D S Haines
September 1997, Cancer causes & control : CCC,
D I Marks, and B W Kurz, and M P Link, and E Ng, and J J Shuster, and S J Lauer, and D Carroll, and I Brodsky, and D S Haines
April 2013, Indian journal of pediatrics,
D I Marks, and B W Kurz, and M P Link, and E Ng, and J J Shuster, and S J Lauer, and D Carroll, and I Brodsky, and D S Haines
June 2009, Medical science monitor : international medical journal of experimental and clinical research,
D I Marks, and B W Kurz, and M P Link, and E Ng, and J J Shuster, and S J Lauer, and D Carroll, and I Brodsky, and D S Haines
February 2022, Scientific reports,
D I Marks, and B W Kurz, and M P Link, and E Ng, and J J Shuster, and S J Lauer, and D Carroll, and I Brodsky, and D S Haines
December 2005, Clinical cancer research : an official journal of the American Association for Cancer Research,
Copied contents to your clipboard!